Carcinoembryonic antigen (CEA) peptides

• US 20070048860A1
• Filed: 12/30/2005
• Published: 03/01/2007
• Est. Priority Date: 10/10/1997
• Status: Abandoned Application

• Current Assignee: Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services
• Original Assignee: The United States of America As Represented By The Secretary of Agriculture
• Inventors: Schlom, Jeffrey, Zaremba, Sam, Salazar, Maria, Hodge, James
• Application Number:
  US11/321,868
• Publication Number:
  US 20070048860A1
• Time in Patent Office: Days
• US Class Current: 435/320.100
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/50 Colon
• CPC Class Codes: A61K 2239/58 Prostate
• CPC Class Codes: A61K 39/001182 Carcinoembryonic antigen [CEA]
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4615 Dendritic cells
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/464482 Carcinoembryonic antigen [CEA]
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2796/00 Viruses not covered by groups C12N2710/00 - C12N2795/00

Abstract

The present invention relates to novel modified CEA agonist (or antagonist) peptides, polypeptides and proteins containing a modified epitope therein, nucleic acids coding therefor, vectors comprising said nucleic acids, mixtures and compositions of the aforementioned agents, and their advantageous use in generating CEA-specific immune responses and/or in the treatment of cancers and the present invention further relates to the foregoing combined with one or more costimulatory molecules.

Claims

1. A CEA agonist polypeptide comprising a modified epitope of CEA, wherein said modified epitope contains the sequence YLSGADLNL (SEQ ID NO:

24).

2. The CEA agonist polypeptide of claim 1 having the sequence of SEQ ID NO:

46 (FIG. 62).

3. A nucleic acid comprising a nucleic acid sequence which encodes the CEA agonist polypeptide of claim 1.

4. The nucleic acid of claim 2 comprising the sequence of SEQ ID NO:

45 (FIG. 62).

5. The nucleic acid of claim 3 wherein the nucleic acid is selected from the group consisting of viral nucleic acid, bacterial DNA, plasmid DNA, naked/free DNA, and RNA.

6. The nucleic acid of claim 5 wherein the viral nucleic acid is selected from the group consisting of adenoviral, alphaviral, and poxviral nucleic acid.

7. The poxviral nucleic acid of claim 6, wherein said nucleic acid is selected from the group consisting of avipox, orthopox, and suipox nucleic acid.

8. The poxviral nucleic acid of claim 7, wherein said nucleic acid is selected from the group consisting of vaccinia, fowlpox, canary pox and swinepox.

9. The poxviral nucleic acid of claim 7, wherein said nucleic acid is selected from the group consisting of TROVAC, NYVAC, ALVAC, MVA, Wyeth, and Poxvac-TC.

10. The nucleic acid of any one of claim 1, further comprising a nucleic acid sequence encoding at least one member selected from the group comprising cytokines, lymphokines, and co-stimulatory molecules.

11. A vector comprising the nucleic acid of claim 1.

12. The vector of claim 11, wherein said vector is selected from the group consisting of recombinant viruses and bacteria.

13. The recombinant virus vector of claim 12, selected from the group consisting of adenovirus, alphavirus and poxvirus.

14. The poxvirus of claim 13, selected from the group consisting of avipox, orthopox, and suipox.

15. The poxvirus of claim 13, selected from the group consisting of vaccinia, fowlpox, canary pox, and swinepox.

16. The poxvirus of claim 14, selected from the group consisting of TROVAC, NYVAC, ALVAC, MVA, Wyeth, and Poxvac-TC.

18. The vector of claim 11 further comprising a nucleic acid sequence encoding at least one member selected from the group consisting of cytokines, lymphokines, and co-stimulatory molecules.

19. A cell comprising a nucleic acid according to claim 1 wherein the cell expresses a CEA agonist polypeptide.

20. A method of inhibiting a CEA epitope expressing carcinoma cell in a patient comprising administering to said patient an effective amount of the CEA agonist polypeptide according to claim 1.

21. The polypeptide of claim 1, wherein said polypeptide is purified.

22. The polypeptide of claim 21, wherein said polypeptide is comprised in a sterile pharmaceutical composition.

23. The vectore of claim 11, wherein said vector is a CEA/TRICOM vector.